Call of Action against Drug Makers False Marketing Strategy

April 30, 2013
Call of Action against Drug Makers False Marketing Strategy To stop drug makers from falsely marketing their products some states are suing and trying to attain more pronounced punishment against the marketers of numerous pharmaceutical medications. It may be noted that it is not illegal for a physician to prescribe a drug that is to be utilized to treat conditions other than those that have been approved by the Food and Drug Administration (FDA). However, it is a violation for the drug manufactures to market their products to do so. The FDA must first approve a prescription drug for any new treatment of a medical condition which will require an across the board thorough clinical trial prior to the drug being marketed for a new condition. As declared by The Wall Street Journal, Johnson and Johnson were previously accused of illegally marketing Risperdal as a safe and effective treatment for some symptoms of dementia among the elderly. Risperdal is only approved by the FDA for treatment of schizophrenia and symptoms of bipolar disorder. In fact, this drug increases the risk of death in the elderly. Johnson and Johnson chose to market the drug for treatment of Alzheimer's; despite the well-known potential adverse reactions for individuals in the demographic. The consumer protection laws which are commonly used to bring suit against harassing debt collectors and dishonest car salesmen are anticipated to be put in practice by individual states instead of the government as a whole, against drug manufactures. Previously these claims and allegations were resolved in huge multi state agreements such as; a settlement from Johnson and Johnson for $181 million dollars. This sum was awarded to compensate thirty-six (36) states and the District of Columbia (DC) on consumer protection claims. Now, for instance; a representative for the Kentucky Office of the Attorney General stated that they opted out of a multistate action against the maker of the drug Avandia stating “they felt they could obtain a better result by taking their own action.” Consumer protection laws will hopefully force pharmaceutical manufacturers to curb their deceptive marketing aimed at unsophisticated consumers who unwittingly place far too much trust in their physicians. For far too long, drug manufacturers have looked at lawsuits filed by plaintiffs as merely a cost of doing business. However, a new waver of lawsuits based on violations of consumer protection laws spearheaded by individual States can result in punitive punishments for pharmaceutical giants. By making unlawful conduct as cost prohibitive as possible, the major drug distributors will be forced to curtail deceptive advertising. Dolman Law Group Accident Injury Lawyers, PA is experienced in litigating claims throughout the State of Florida on behalf of injury victims in regards to violations of safety rules. As dangerous drug attorneys, we offer a free consultation and case evaluations. The laywers that comprise the Dolman Law Group Accident Injury Lawyers, PA are legal advocates for bodily harms. We are presently reviewing claims throughout the State of Florida related to Risperdal, Actos, Mirena IUD, Pradaxa, Zithromax, Yaz and Nuvaring among others. (833) 606-DRUG [3784].

Matthew Dolman

Clearwater Personal Injury and Insurance Attorney

This article was written and reviewed by Matthew Dolman. Matt has been a practicing civil trial, personal injury, products liability, and mass tort lawyer since 2004. He has represented over 11,000 injury victims and has served as lead counsel in over 1000 lawsuits. Matt is a lifetime member of the Million Dollar Advocates Forum and Multi-Million Dollar Advocates Forum for resolving individual cases in excess or $1 million and $2 million, respectively. He has also been selected by his colleagues as a Florida Superlawyer and as a member of Florida’s Legal Elite on multiple occasions. Further, Matt has been quoted in the media numerous times and is a sought-after speaker on a variety of legal issues and topics.

Learn More